Triiodothyronine-stimulated dendritic cell vaccination boosts antitumor immunity against murine colon cancer

SOLER MARIA FLORENCIA; ROCIO MIANA; DANA NEGRETTI; PAULA SUBIRADA; VANINA ALAMINO; MARIA CECILIA SANCHEZ; ANA CAROLINA DONADIO; CLAUDIA PELLIZAS; MA.DEL MAR MONTESINOS

INTERNATIONAL IMMUNOPHARMACOLOGY

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2022

1567-5769

iven the ability of dendritic cells (DCs) to modulate other immune players, their manipulation holds greatpotential for inducing efficient antitumor immunity. However, DC vaccine manufacturing deserve optimizationsince tumor cell cargo and DC functional state induced by maturation signals influence their in vivo immunogenicpotential. We reported that triiodothyronine (T3) stimulates mice DCs? maturation and their ability to promotepro-inflammatory and cytotoxic T-cell responses. This study aimed to evaluate the efficacy of T3-conditioned DCvaccination in a murine model of colon carcinoma, deciphering the molecular players involved; and to examinethe effects of T3 on the maturation and activation of human DCs (huDCs). Bone marrow-derived DCs wereexposed to T3 and MC38 cancer cells that underwent cell death (MC38-Apo/Nec) by UVB irradiation. Our resultsshowed that MC38-Apo/Nec cells are efficiently uptaken by DCs and that T3 upregulates CD86 expression withincreased production of the pr